ARTICLE | Product Development
Picking vaccine strategies that could hold up to COVID variants
COVID vaccines that induce broad polyclonal responses or potently enlist T cells could upstage single-antigen products when it comes to variants
February 6, 2021 3:38 AM UTC
As new mutations to SARS-CoV-2 emerge faster than many countries can vaccinate their populations, pressure is mounting on vaccine developers to pre-empt the variants before they take hold, let alone are properly characterized.
And while the first wave of vaccines set a new standard for innovation, efficacy and speed, they may be the most vulnerable to escape variants because they all target a single antigen: the spike protein. ...